BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $45 from $40 and keeps a Buy rating on the shares. The company reported “another strong beat and raise” quarter and delivered its second consecutive quarter of GAAP profit, the analyst tells investors in a research note. The firm continues to see a positive risk/reward on the stock. It is “very much possible” for Novitas to continue payment for Castle’s squamous cell carcinoma test beyond Q4, noting Castle been getting paid for 2.5 years now and has done a good job generating additional evidence and data that may warrant continued Medicare reimbursement coverage.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CSTL:
- Castle Biosciences price target raised to $40 from $34 at Lake Street
- Castle Biosciences price target raised to $39 from $37 at Baird
- Castle Biosciences price target raised to $36 from $28 at KeyBanc
- Castle Biosciences Reports Strong Q3 2024 Growth
- Castle Biosciences Reports Strong Q3 2024 Performance
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
